Drug Delivery for Treatment of Neurodegenerative Diseases

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Delivery and Controlled Release".

Deadline for manuscript submissions: closed (30 April 2020) | Viewed by 8992

Special Issue Editors

Department of Pharmacy, University G. d’Annunzio, Via dei Vestini, 66100 Chieti, Italy
Interests: drug delivery systems; CNS drug delivery; neurodegenerative disorders
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The failure of many molecules as CNS pharmacologically active compounds is due to different restrictions, such as poor water solubility, reduced intestinal absorption, in vivo stability, bioavailability, plasma fluctuation levels, and difficulties crossing the blood–brain barrier (BBB). Nanotechnology-based approaches, employing liposomes, micelles, dendrimers, and solid lipid nanoparticles (SLN) as drug delivery systems, are used to overcome the above-reported limitations. During the last few decades, new drug delivery technologies have emerged to treat neurodegenerative diseases; these formulations have the ability to protect drugs from chemical and enzymatic degradation, deliver the active compound to the target site with a substantial reduction of systemic toxicity, and pass physiological barriers, increasing bioavailability without resorting to high dosage forms. The aim of this Special Issue is to highlight current progress in the use of new drug delivery technologies to overcome the BBB and to target drugs to the CNS. 

Prof. Antonio Di Stefano
Dr. Lisa Marinelli
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Neurodegenerative diseases
  • New therapeutic strategies
  • Drug delivery systems
  • Nanotechnology-based approaches
  • Brain targeting

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

17 pages, 3776 KiB  
Article
Pharmacotechnical Development of a Nasal Drug Delivery Composite Nanosystem Intended for Alzheimer’s Disease Treatment
Pharmaceutics 2020, 12(3), 251; https://doi.org/10.3390/pharmaceutics12030251 - 11 Mar 2020
Cited by 37 | Viewed by 5397
Abstract
Direct nose-to-brain delivery has been raised as a non-invasive powerful strategy to deliver drugs to the brain bypassing the blood-brain barrier (BBB). This study aimed at preparing and characterizing an innovative composite formulation, associating the liposome and hydrogel approaches, suitable for intranasal administration. [...] Read more.
Direct nose-to-brain delivery has been raised as a non-invasive powerful strategy to deliver drugs to the brain bypassing the blood-brain barrier (BBB). This study aimed at preparing and characterizing an innovative composite formulation, associating the liposome and hydrogel approaches, suitable for intranasal administration. Thermosensitive gel formulations were obtained based on a mixture of two hydrophilic polymers (Poloxamer 407, P407 and Poloxamer 188, P188) for a controlled delivery through nasal route via liposomes of an active pharmaceutical ingredient (API) of potential interest for Alzheimer’s disease. The osmolarity and the gelation temperature (T° sol-gel) of formulations, defined in a ternary diagram, were investigated by rheometry and visual determination. Regarding the issue of assays, a mixture composed of P407/P188 (15/1%, w/w) was selected for intranasal administration in terms of T° sol-gel and for the compatibility with the olfactory mucosal (280 ± 20 mOsmol, pH 6). Liposomes of API were prepared by the thin film hydration method. Mucoadhesion studies were performed by using mucin disc, and they showed the good natural mucoadhesive characteristics of in situ gel formulations, which increased when liposomes were added. The study demonstrated successful pharmacotechnical development of a promising API-loaded liposomes in a thermosensitive hydrogel intended for nasal Alzheimer’s disease treatment. Full article
(This article belongs to the Special Issue Drug Delivery for Treatment of Neurodegenerative Diseases)
Show Figures

Graphical abstract

10 pages, 6154 KiB  
Article
Spatial Distribution of (R)-salbutamol in Rat Brain Following Nasal and Intravenous Administration Using DESI-MS
Pharmaceutics 2020, 12(1), 35; https://doi.org/10.3390/pharmaceutics12010035 - 02 Jan 2020
Cited by 5 | Viewed by 3253
Abstract
Recent studies have shown that β2-Adrenoreceptor is a regulator of the a-synuclein gene driving risk of Parkinson’s disease. The β2-AR agonist (R)-salbutamol, eutomer of rac-salbutamol, may hold therapeutic potential for Parkinson’s disease (PD) following nasal administration. In this study, we use desorption electrospray [...] Read more.
Recent studies have shown that β2-Adrenoreceptor is a regulator of the a-synuclein gene driving risk of Parkinson’s disease. The β2-AR agonist (R)-salbutamol, eutomer of rac-salbutamol, may hold therapeutic potential for Parkinson’s disease (PD) following nasal administration. In this study, we use desorption electrospray ionization mass spectrometry (DESI-MS) to analyze spatial distribution of (R)-salbutamol in rat brain following nasal and intravenous administration. Here, we report that (R)-salbutamol efficiently deliver to the brain and had more drug dosage exposure in rat’s brain through nasal route administration than that of intravenous route administration. In conclusion, administering (R)-salbutamol through nasal route of administration may hold advantages in improving spatial distribution and increased exposure of drug in brain. Full article
(This article belongs to the Special Issue Drug Delivery for Treatment of Neurodegenerative Diseases)
Show Figures

Graphical abstract

Back to TopTop